Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Bonus News from MarketBeat A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHReported by Nathan Reiff. Published: 2/12/2026. 
Quick Look - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
Earnings in the healthcare sector give investors a clear view into a company's pipeline and development progress. Even well-established firms can surprise with growth when a new drug or device gains traction, and earnings season is an opportunity for management to add context beyond FDA approvals and other regulatory news. When several healthcare companies report on the same day, investors must sift through multiple updates to plan trades. On Feb. 10, 2025, three major names—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—reported full-year and Q4 2025 results. Below are the highlights and takeaways for healthcare investors. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance Watch Now! Porter Stansberry & Luke Lango join forces to unveil:
The Three Titanic Forces Converging To Unleash A New 1776 Moment
"We have never seen wealth created at this size and speed" MIT Researcher Click here for the stocks to buy and sell now U.K.-based AstraZeneca closed 2025 by reinforcing its position in oncology, which made up roughly 44% of product sales in the quarter. Sales of key cancer drugs such as Imfinzi and Enhertu rose as much as 48% year-over-year, helping total revenue increase 8.6% to $58.7 billion for the quarter. After-tax profit rose sharply alongside revenue, climbing to $10.2 billion from $7 billion in the year-ago quarter. The board declared a second interim dividend that is 7 cents higher than last year's. Investors have additional catalysts ahead: management said about 20 Phase 3 readouts are expected in 2026, and the company expects solid increases in both total revenue and core earnings per share for the full year 2026. Shares of AZN rose nearly 3% in the hours after the company released its strong earnings report. While 10 of 11 analysts rate AZN a Buy or equivalent, Wall Street's consensus price target of $95.75 implies downside of about 51% from current levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Be Mindful of Earnings and Margin Limitations Edwards, known for replacement heart valves and related devices, reported largely positive Q4 2025 results. Sales rose 13.3% year-over-year, driven by strong transcatheter aortic valve replacement (TAVR) demand and uptake of the latest SAPIEN valve. However, adjusted EPS missed analysts' expectations, and gross profit margin declined by 0.8 percentage points year-over-year. Despite the mixed read, Edwards reiterated its prior 2026 outlook, which called for sales growth of 8%–10% year-over-year and EPS of $2.90–$3.05. EW shares jumped above $80 in after-hours trading—about 4% above the prior close—following the earnings release. About two-thirds of analysts covering EW rate the shares a Buy, and Wall Street's consensus target price sits near $96.77, implying roughly 25% upside. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Going Forward Zimmer Biomet, which makes joint replacement systems and implants, reported EPS of $2.42—$0.04 above consensus—and revenue of $2.2 billion, up nearly 11% year-over-year, slightly ahead of estimates. Robust demand for orthopedic products supported both top- and bottom-line growth, and shares rose more than 3% in the hours after the announcement. The company is shifting focus toward the U.S. market, which accounts for roughly 60% of sales. With insured patients continuing to increase utilization, near-term demand for Zimmer's products is expected to remain elevated. That said, tariffs could weigh on margins and overall results in 2026. Management issued conservative guidance in the earnings report, forecasting adjusted EPS of $8.30–$8.45 and free cash flow improvement of 8%–10%. Before the earnings release, analysts were divided on Zimmer, and the consensus rating was a Hold despite about 15% of projected upside.
| 
